ArticleOPEN ACCESS

Erythema multiforme following COVID-19 vaccination (BNT162b2)

Hautarzt
DOI: 10.1007/s00105-021-04911-4
10Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We report a case of a patient with erythema multiforme major following COVID-19 (coronavirus disease 2019) vaccination. Lesions on skin and mucous membranes developed 48 h after the second dose of the mRNA-vaccine BNT162b2 (Tozinameran, Comirnaty®). Under the application of external glucocorticoids complete resolution was achieved within 3 weeks.

Author supplied keywords

Cite

CITATION STYLE

APA

Wunderlich, K., & Dirschka, T. (2022, January 1). Erythema multiforme following COVID-19 vaccination (BNT162b2). Hautarzt. Springer Medizin. https://doi.org/10.1007/s00105-021-04911-4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free